Amanta Healthcare Limited has issued a correction regarding its solar power plant agreement with Zodiac Energy Limited, rectifying a significant clerical error in the project capacity. The company disclosed on January 02, 2026, that the solar power plant capacity was erroneously mentioned as 10.8 KWp in the earlier intimation dated December 30, 2025, whereas the correct capacity is 10.8 MWp.

Corrected Solar Power Plant Specifications

To rectify the clerical error, Amanta Healthcare re-executed the agreement on January 02, 2026, with Zodiac Energy Limited. The corrected project details are presented below:

Agreement Re-execution Details

Zodiac Energy Limited, headquartered at 5 Upper Ground Floor, Milestone Building, Nr. Drive-In Cinema, Thaltej, Ahmedabad, Gujarat - 380054, remains the installation partner for the solar power project. The company emphasized that except for the capacity correction, there are no changes in the terms and conditions of the agreement as previously executed.

Regulatory Compliance Information

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided detailed information in accordance with multiple SEBI circulars, confirming that:

Future Commitments

Amanta Healthcare has reiterated its commitment to provide comprehensive information regarding the solar power plant upon successful commissioning. The company stated that detailed disclosures will be made in accordance with regulatory requirements once the installation event is completed and the plant becomes operational.

The significant capacity increase from 10.8 KWp to 10.8 MWp represents a substantial enhancement in the project scale, with the corrected capacity being 1,000 times larger than initially reported. This solar power initiative positions Amanta Healthcare to significantly reduce its operational energy costs while advancing its sustainability objectives through renewable energy adoption.

Amanta Healthcare Limited , a prominent pharmaceutical company, has reported progress in utilizing its Initial Public Offering (IPO) proceeds for the quarter ended September 30, 2025. The company has allocated funds towards its expansion plans, focusing on enhancing manufacturing capabilities at its Gujarat facility.

Key Highlights of Fund Utilization

• Total Utilization: Amanta Healthcare has utilized Rs 3,030.02 lakhs from its IPO proceeds during the quarter.
• Primary Focus: The funds were primarily directed towards capital expenditure, including manufacturing equipment and civil construction work.
• Remaining Funds: The company still has Rs 9,569.98 lakhs available for further planned expansions.

Detailed Breakdown of Fund Allocation

Expansion Plans

1. SteriPort Manufacturing Line:

   • Planned commencement: January 2026
   • Location: Hariyala, Kheda, Gujarat

2. SVP (Small Volume Parenterals) Manufacturing Line:

   • Planned commencement: January 2027
   • Location: Hariyala, Kheda, Gujarat

Financial Performance

Amanta Healthcare's recent financial results for the quarter ended September 30, 2025, show:

Management Commentary

Bhavesh Patel, Chairman & Managing Director of Amanta Healthcare, stated, "Our strategic utilization of IPO proceeds is aligned with our growth objectives. The investments in new manufacturing lines for SteriPort and SVP will significantly enhance our production capabilities and market position."

Future Outlook

The company's focus on expanding its manufacturing capabilities, particularly in SteriPort and SVP lines, indicates its commitment to growth and market expansion. The utilization of IPO funds and the planned commencement of new production lines in 2026 and 2027 suggest a roadmap for Amanta Healthcare's future development.

Investors and market analysts will likely monitor the progress of these expansion projects and their potential impact on the company's future financial performance and market position in the pharmaceutical sector.